Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
Stroke Risk in AF Patients on Rivaroxaban or Warfarin Stroke Risk in AF Patients on Rivaroxaban or Warfarin
This study compared the risk of stroke and all-cause mortality in patients taking rivaroxaban or warfarin for nonvalvular atrial fibrillation.Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
AUGUSTUS: Apixaban Bests Warfarin Despite Prior Stroke AUGUSTUS: Apixaban Bests Warfarin Despite Prior Stroke
In a prespecified secondary analysis of patients with a history of stroke, TIA, or thromboembolism, apixaban maintained an advantage over warfarin.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 10, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Minorities With ESRD and Afib Less Likely to Fill Prescriptions for Warfarin Minorities With ESRD and Afib Less Likely to Fill Prescriptions for Warfarin
Minority patients with end-stage renal disease (ESRD) and atrial fibrillation were less likely than whites to fill warfarin prescriptions, even though they were more likely to experience a stroke, researchers say.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 27, 2020 Category: Intensive Care Tags: Nephrology News Source Type: news
Secondary analysis confirms safety of blood thinning agent
(American Heart Association) The blood thinner apixaban, which treats and prevents blood clots in some people with irregular heart rhythm, is safe and effective in stroke patients. Apixaban is associated with less bleeding, death and hospitalization than warfarin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 21, 2020 Category: International Medicine & Public Health Source Type: news
Warfarin Administration Time and Anticoagulation Stability Warfarin Administration Time and Anticoagulation Stability
Does it really matter if warfarin is taken in the evening or the morning?Annals of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Compared With Warfarin, Non-Vitamin K Antagonist Oral Anticoagulants May Better Limit Risks to Bone Health
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - January 25, 2020 Category: Orthopaedics Tags: Trends and Innovations Source Type: news
Time of Day for Taking Warfarin Does Not Matter
WEDNESDAY, Jan. 22, 2020 -- Time of day for taking warfarin makes no difference on the drug ' s effectiveness, according to a study published in the January/February issue of the Annals of Family Medicine.
Scott R. Garrison, M.D., Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 22, 2020 Category: Pharmaceuticals Source Type: news
Do You Take Warfarin? Time of Day Might Not Matter
FRIDAY, Jan. 17, 2020 -- Patients taking the blood thinner warfarin have been told that it should be taken at night, but a new study found the time of day doesn ' t matter. " Whether warfarin is taken in the morning, or the evening, its therapeutic... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 17, 2020 Category: General Medicine Source Type: news
Fracture Risk Higher With Warfarin Vs DOACs Fracture Risk Higher With Warfarin Vs DOACs
Warfarin is associated with an increased risk of fractures compared with a direct oral anticoagulant (DOAC), a large real-world analysis has found.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 28, 2019 Category: Orthopaedics Tags: Cardiology News Source Type: news
Delayed intracranial hemorrhage in anticoagulated geriatric patients after ground level falls - Cocca AT, Privette A, Leon SM, Crookes BA, Hall G, Lena J, Eriksson EA.
BACKGROUND: The reported risk of delayed intracranial hemorrhage (ICH) in a trauma patient on warfarin is estimated to be between 0.6% and 6%. The risk of delayed ICH in trauma patients taking novel oral anticoagulants (NOACs) is not well-defined. ... (Source: SafetyLit)
Source: SafetyLit - November 23, 2019 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Risks After GI Bleeding in Anticoagulant, Antiplatelet Users Risks After GI Bleeding in Anticoagulant, Antiplatelet Users
When is it safe to resume aspirin or warfarin therapy after a major GI bleed?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Low-Intensity Warfarin Not Noninferior in Hip, Knee Surgery
TUESDAY, Nov. 5, 2019 -- Among older patients undergoing hip or knee replacement, low-intensity compared with standard-intensity warfarin prophylaxis did not meet the noninferiority criterion for the composite outcome of risk of venous... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 5, 2019 Category: Pharmaceuticals Source Type: news
DOACs Tied to Lower Fracture Risk vs Warfarin in AF DOACs Tied to Lower Fracture Risk vs Warfarin in AF
An observational study suggests all oral anticoagulants are not created equal: treatment with DOACs was associated with a lower risk for osteoporotic fractures than warfarin.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 22, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Rivaroxaban Misfires in Antiphospholipid Syndrome Rivaroxaban Misfires in Antiphospholipid Syndrome
Rivaroxaban not only failed to show noninferiority to warfarin, but trended toward higher thrombosis risk in patients with APS.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
